Lisata Therapeutics, Inc.

Name: Lisata Therapeutics, Inc. standardized financial statements, quarterly
Creator: Listed

LSTANasdaqCIK 320017HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q2 FY2026

Operating income−$4.0m, Q2 FY2026

Net income−$2.9m, Q2 FY2026

Lisata Therapeutics, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$k	0.0	0.0	0.0	0.0	0.0	1,000	0.0	70.0	0.0	100	0.0	0.0
Cost of revenue	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Gross profit	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Research and development	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Selling, general and administrative	$k	2,584	3,012	3,360	2,922	2,794	not reported	3,245	2,685	2,455	not reported	not reported	not reported
Operating income	$k	(5,964)	(6,025)	(6,601)	(5,523)	(5,336)	(4,949)	(5,847)	(4,868)	(4,414)	(3,079)	(4,942)	(3,992)
Interest expense	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Income tax	$k	0.0	0.0	(798)	0.0	0.0	0.0	(962)	0.0	0.0	0.0	(387)	0.0
Net income	$k	(5,261)	(5,365)	(5,401)	(5,044)	(4,930)	(4,610)	(4,724)	(4,659)	(4,249)	(2,954)	(4,489)	(2,929)
Diluted EPS	$ per share	(0.65)	not reported	(0.65)	(0.61)	(0.59)	not reported	(0.55)	(0.54)	(0.49)	not reported	(0.50)	(0.32)
Basic EPS	$ per share	(0.65)	not reported	(0.65)	(0.61)	(0.59)	not reported	(0.55)	(0.54)	(0.49)	not reported	(0.50)	(0.32)

Balance sheet

Cash and equivalents$10.4m, Q2 FY2026

Shareholders' equity$8.2m, Q2 FY2026

Lisata Therapeutics, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	32.4	22.6	21.8	28.3	19.5	16.2	20.2	16.8	19.0	16.0	13.1	10.4
Current assets	$m	57.2	53.9	47.6	42.0	37.7	34.6	28.6	24.9	21.6	17.7	14.0	11.0
Total assets	$m	58.1	54.7	48.2	42.6	38.2	35.0	29.0	25.2	21.8	17.7	14.1	11.0
Current liabilities	$m	5.1	6.6	5.3	4.5	4.7	5.6	3.8	4.3	4.6	3.1	3.3	3.0
Total liabilities	$m	5.4	6.8	5.5	4.6	4.8	5.7	3.9	4.4	4.6	3.1	3.4	3.0
Long-term debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Current portion of debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	53.0	48.1	43.0	38.2	33.7	29.6	25.4	21.0	17.4	14.9	10.9	8.2

Cash flow

Operating cash flow−$2.6m, Q2 FY2026

Capital expenditure$0, Q2 FY2026

Lisata Therapeutics, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(3,583)	(4,069)	(7,027)	(5,283)	(2,518)	(4,528)	(5,402)	(3,956)	(3,342)	(3,249)	(3,083)	(2,649)
Capital expenditure	$k	0.0	0.0	0.0	0.0	0.0	0.0	28.0	0.0	0.0	0.0	0.0	0.0
Dividends paid	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)9.11m, Q2 FY2026

Lisata Therapeutics, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	k shares	4,747	7,987	8,021	8,141	8,294	8,308	8,321	8,602	8,605	8,738	9,006	9,106

Shares outstanding: 9.01m at Aug 6, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:22 ET. Listed shows no prices and gives no investment advice.